Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Haber

Showing results (61-70 of 186) with videos related to

Pageof 19
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 30, 2022
Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitorsKsenia A Novototskaya-Vlasova, Nickolay S Neznanov, Ivan Molodtsov, et al.
British Journal of Haematology|June 9, 2009
Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemiaRosemary Sutton, Nicola C Venn, Jonathan Tolisano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemiaGlenn M Marshall, Michelle Haber, Edward Kwan, et al.
Oncotarget|June 23, 2014
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1Jeyran Shahbazi, Christopher J Scarlett, Murray D Norris, et al.
Cancers|September 28, 2021
Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric SarcomaRachael L Terry, Deborah Meyran, Emmy D G Fleuren, et al.
Plos One|October 23, 2013
Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual diseaseMawar Karsa, Luciano Dalla Pozza, Nicola C Venn, et al.
Oncotarget|February 6, 2016
The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expressionAndrew E Tee, Bing Liu, Renhua Song, et al.
Molecular Cancer Research : MCR|June 23, 2011
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cellsAntonio Porro, Nunzio Iraci, Simona Soverini, et al.
Blood|February 7, 2004
Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapiesNatalia L M Liem, Rachael A Papa, Christopher G Milross, et al.
Cancer Research|December 29, 2011
N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastomaJamie I Fletcher, Samuele Gherardi, Jayne Murray, et al.
Pageof 19

Showing results (61-70 of 186) with videos related to

Sort By:
Pageof 19
Proceedings of the National Academy of Sciences of the United States of America|November 30, 2022
Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitorsKsenia A Novototskaya-Vlasova, Nickolay S Neznanov, Ivan Molodtsov, et al.
British Journal of Haematology|June 9, 2009
Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemiaRosemary Sutton, Nicola C Venn, Jonathan Tolisano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemiaGlenn M Marshall, Michelle Haber, Edward Kwan, et al.
Oncotarget|June 23, 2014
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1Jeyran Shahbazi, Christopher J Scarlett, Murray D Norris, et al.
Cancers|September 28, 2021
Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric SarcomaRachael L Terry, Deborah Meyran, Emmy D G Fleuren, et al.
Plos One|October 23, 2013
Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual diseaseMawar Karsa, Luciano Dalla Pozza, Nicola C Venn, et al.
Oncotarget|February 6, 2016
The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expressionAndrew E Tee, Bing Liu, Renhua Song, et al.
Molecular Cancer Research : MCR|June 23, 2011
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cellsAntonio Porro, Nunzio Iraci, Simona Soverini, et al.
Blood|February 7, 2004
Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapiesNatalia L M Liem, Rachael A Papa, Christopher G Milross, et al.
Cancer Research|December 29, 2011
N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastomaJamie I Fletcher, Samuele Gherardi, Jayne Murray, et al.
Pageof 19